1 / 14

ACR 　レポート

ACR 　レポート . 熊本大学大学院医学薬学研究部皮膚機能病態学 熊本大学医学部附属病院皮膚科 熊本大学医学部附属病院形成・再建科 尹　浩信. ACR 2007 Annual Scientific Meeting. November 6-11, 2007 Boston Convention and Exhibition Center Boston, MA. Sclerodermna に関する Abstracts. 105 abstracts 日本から 13 abstracts. ACR Concurrent Session.

ide
Download Presentation

ACR 　レポート

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACR　レポート 熊本大学大学院医学薬学研究部皮膚機能病態学 熊本大学医学部附属病院皮膚科 熊本大学医学部附属病院形成・再建科 尹　浩信

  2. ACR 2007 Annual Scientific Meeting November 6-11, 2007 Boston Convention and Exhibition Center Boston, MA

  3. Sclerodermnaに関するAbstracts • 105 abstracts • 日本から13 abstracts

  4. ACR Concurrent Session • Pathogenesis of systemic sclerosis: Key pathways and molecular targets for therapy

  5. 2144. Ghosh AK, et al. Novel function of PPAR: Endogenous anti-fibrotic that ameliorates murine scleroderma and may be defective in systemic sclerosis (SSc).

  6. Ligands of PPAR →adipogenic differentiation TGF-→ PPARexpression↓ PPARexpression↓ in SSc skin Ligands of PPARameliorated cuatneous fibrosis in murine model of scleroderma.

  7. 2146. Shiwen X, et al. Imatinib alleviates the pro-fibrotic phenotype of scleroderma fibroblasts.

  8. SSc fibroblasts: c-Abl↑, ERK↑,matrix proteins↑ PDGFR blockade: c-Abl↓, ERK ↓, type I collagen ↓, CTGF→ in SSc fibroblasts c-Abl↑, ERK↑ contribute the fibrosis in SSc

  9. ACR Concurrent Session • Systemic sclerosis, fibrosing syndromes and Raynaud’s: Clinical aspects and therapeutics

  10. 2163. Chung L, et al. A multi-center placebo-controlled “in-life” study of MQX-503 in patients with Raynaud phenomenon.

  11. 2165. Chung L, et al. MQX-503, a novel topical nitroglycerin formulation, improves severity of Raynaud phenomenon in a heterogenous patient population.

  12. MQX-503はplaceboと比較して、有意にRaynaud condition scoreを改善。 • 早期に有効。 • Secondary Raynaud よりはprimary Raynaudに有効

  13. 2167. Pakozdi A, et al. Addition of the short term phosphodiesterase-5 inhibitor Sildenafil to iloprost therapy for scleroderma digital vasculopathy.

  14. 10例の女性SSc患者（5dcSSc、5lcSSc） • Sildenafil内服6週後に判定 • 6例に有効 • 5例で潰瘍治癒 • Clinical responderではthermographyにて平均 3.6℃指尖温度が上昇

More Related